Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Payables: 2016-2025

Historic Payables for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $7.6 million.

  • Collegium Pharmaceutical's Payables rose 143.38% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year increase of 98.97%. This contributed to the annual value of $3.9 million for FY2024, which is 54.74% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Payables of $7.6 million as of Q3 2025, which was down 29.78% from $10.9 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Payables peaked at $17.9 million during Q1 2025, and registered a low of $2.4 million during Q2 2024.
  • Moreover, its 3-year median value for Payables was $3.9 million (2024), whereas its average is $6.3 million.
  • In the last 5 years, Collegium Pharmaceutical's Payables tumbled by 63.48% in 2023 and then skyrocketed by 351.49% in 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Payables (Quarterly) stood at $4.2 million in 2021, then dropped by 16.59% to $3.5 million in 2022, then surged by 148.77% to $8.7 million in 2023, then slumped by 54.74% to $3.9 million in 2024, then soared by 143.38% to $7.6 million in 2025.
  • Its Payables stands at $7.6 million for Q3 2025, versus $10.9 million for Q2 2025 and $17.9 million for Q1 2025.